Skip to main content
Top
Published in: Annals of Hematology 9/2023

02-06-2023 | Secondary Hemophagocytic Lymphohistiocytosis | Original Article

Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis

Authors: Qiaolei Zhang, Lixia Zhu, De Zhou, Li Li, Wanzhuo Xie, Yamin Tan, Xiujin Ye

Published in: Annals of Hematology | Issue 9/2023

Login to get access

Abstract

The aim of our study was to summarize the clinical characteristics of early death patients with newly diagnosed secondary hemophagocytic lymphohistiocytosis (sHLH), analyze the risk factors of early death, and analyze the survival of patients. The clinical characteristics of 324 newly diagnosed sHLH patients admitted to the First Affiliated Hospital of Zhejiang University Medical College and Zhejiang Provincial Cancer Hospital from January 2014 to February 2021 were analyzed retrospectively. Analyze the independent risk factors of early death, compare the secondary diseases and treatment methods of patients with early death group and non early death group, and analyze the survival of all patients with sHLH. Among the 324 newly diagnosed patients with sHLH, 134 died early, with an early mortality rate of 41.4%. Comparing the clinical characteristics of patients with early death group and patients with non early death group, logistic regression model was used to conduct multifactor analysis. Age > 60 years, Plt ≤ 20.0 × 109/L, APTT > 36.0 s and LDH > 1000.0 U/L were independent risk factors for early death of newly diagnosed sHLH patients (P < 0.05). Comparing the secondary diseases and treatment methods between early death group and non early death group, the proportion of sHLH patients secondary to lymphoma was higher in early death group than that in non early death group (P < 0.05). The proportion of sHLH patients secondary to connective tissue disease and infection was lower in early death group than that in non early death group (P < 0.05), and the proportion of sHLH patients used hormone combined chemotherapy was lower in early death group than that in non early death group (P < 0.05). The median follow-up time of all patients was 12.0 (1–65) months. The 5-year OS rates of patients with age > 60 years and age ≤ 60 years were 25.8% and 49.6% respectively (P < 0.001); The 5-year OS rates of patients with Plt > 20.0 × 109/L and Plt ≤ 20.0 × 109/L were 52.5% and 25.5% respectively (P < 0.001); The 5-year OS rates of patients with APTT > 36.0 s and APTT ≤ 36.0 s were 34.5% and 57.4% respectively (P < 0.001); The 5-year OS rates of patients with LDH > 1000.0 U/L and LDH ≤ 1000.0 U/L were 23.3% and 56.3% respectively (P < 0.001). Age > 60 years, Plt ≤ 20.0 × 109/L, APTT > 36.0 s and LDH > 1000.0 U/L are independent risk factors for early death of sHLH patients. The early mortality of lymphoma associated HLH (LA-HLH) patients is high, and early use of hormone combined chemotherapy can reduce the early mortality.
Literature
1.
go back to reference La Rosée P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JAM, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465–2477. https://doi.org/10.1182/blood.2018894618CrossRefPubMed La Rosée P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JAM, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465–2477. https://​doi.​org/​10.​1182/​blood.​2018894618CrossRefPubMed
5.
go back to reference Tang S, Zhao C, Chen W (2020) Aggressive diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: report of one case. Int J Clin Exp Pathol 13(9):2392–2396. eCollection2020PubMedPubMedCentral Tang S, Zhao C, Chen W (2020) Aggressive diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: report of one case. Int J Clin Exp Pathol 13(9):2392–2396. eCollection2020PubMedPubMedCentral
9.
go back to reference Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG (2016) Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857–2866. https://doi.org/10.1002/cncr.30084CrossRefPubMed Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG (2016) Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857–2866. https://​doi.​org/​10.​1002/​cncr.​30084CrossRefPubMed
11.
go back to reference Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P (2020) Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol 146(4):1065–1077. https://doi.org/10.1007/s00432-020-03139-4CrossRefPubMedPubMedCentral Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P (2020) Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol 146(4):1065–1077. https://​doi.​org/​10.​1007/​s00432-020-03139-4CrossRefPubMedPubMedCentral
15.
go back to reference Bigenwald C, Fardet L, Coppo P, Meignin V, Lazure T, Fabiani B, Kohn M, Oksenhendler E, Boutboul D, Uzzan M, Lambotte O, Galicier L (2018) A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. Br J Haematol 183(1):68–75. https://doi.org/10.1111/bjh.15506CrossRefPubMed Bigenwald C, Fardet L, Coppo P, Meignin V, Lazure T, Fabiani B, Kohn M, Oksenhendler E, Boutboul D, Uzzan M, Lambotte O, Galicier L (2018) A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. Br J Haematol 183(1):68–75. https://​doi.​org/​10.​1111/​bjh.​15506CrossRefPubMed
25.
go back to reference Paul T, Kalra M, Danewa A, Sachdeva P, Thatikonda KB, Sachdeva D, Sachdeva A (2022) Pediatric Hemophagocytic Lymphohistiocytosis - A Single Center Study. Indian Pediatr 59(4):283–286CrossRefPubMed Paul T, Kalra M, Danewa A, Sachdeva P, Thatikonda KB, Sachdeva D, Sachdeva A (2022) Pediatric Hemophagocytic Lymphohistiocytosis - A Single Center Study. Indian Pediatr 59(4):283–286CrossRefPubMed
28.
go back to reference Tong HY, Ren YL, Liu H, Xiao F, Mai WY, Meng HT, Qian WB, Huang J, Mao LP, Tong Y, Wang L, Qian JJ, Jin J (2008) Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma 49(1):81–87. https://doi.org/10.1080/10428190701713630CrossRefPubMed Tong HY, Ren YL, Liu H, Xiao F, Mai WY, Meng HT, Qian WB, Huang J, Mao LP, Tong Y, Wang L, Qian JJ, Jin J (2008) Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma 49(1):81–87. https://​doi.​org/​10.​1080/​1042819070171363​0CrossRefPubMed
29.
go back to reference Li F, Li P, Zhang R, Yang G, Ji D, Huang X, Xu Q, Wei Y, Rao J, Huang R, Chen G (2014) Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol 31:902. https://doi.org/10.1007/s12032-014-0902-yCrossRefPubMed Li F, Li P, Zhang R, Yang G, Ji D, Huang X, Xu Q, Wei Y, Rao J, Huang R, Chen G (2014) Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol 31:902. https://​doi.​org/​10.​1007/​s12032-014-0902-yCrossRefPubMed
32.
go back to reference Zhou L, Liu Y, Wen Z, Yang S, Li M, Zhu Q, Qiu S, Gao Y, Wang H, Yuan Y, Zhang H, Chen C, Zeng W, Guan Z, Pan X (2020) Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome. J Cancer Res Clin Oncol 146(11):3063–3074. https://doi.org/10.1007/s00432-020-03301-yCrossRefPubMed Zhou L, Liu Y, Wen Z, Yang S, Li M, Zhu Q, Qiu S, Gao Y, Wang H, Yuan Y, Zhang H, Chen C, Zeng W, Guan Z, Pan X (2020) Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome. J Cancer Res Clin Oncol 146(11):3063–3074. https://​doi.​org/​10.​1007/​s00432-020-03301-yCrossRefPubMed
Metadata
Title
Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis
Authors
Qiaolei Zhang
Lixia Zhu
De Zhou
Li Li
Wanzhuo Xie
Yamin Tan
Xiujin Ye
Publication date
02-06-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05153-1

Other articles of this Issue 9/2023

Annals of Hematology 9/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.